R&D Changing Faces: Board of Directors and Advisory Boards, Febr... Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.
R&D Ending trial-and-error: How psychedelics and precision medic... The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
R&D Regulatory setback or scientific signal? The case for human-... Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
R&D Longevity is not a consumer trend, but a pipeline strategy p... Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.
R&D Making AI work where it matters, with Rob DiCicco Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
